Treatment of Nausea and Vomiting Related to Anti-Cancerous Multiple Combination Chemotherapy: Results of Two Controlled Studies

Abstract

Two controlled double-blind studies were carried out successively on a cancerous out-patient population receiving multiple combination chemotherapy at successive treatment courses to show the anti-emetic efficiency of metopimazine compared to a placebo. The patient was taken as his own control and the treatment, order was randomly selected.

The first trial

▄ consisting of sixty-seven patients, showed a weak statistically significant difference (0.05 < p < 0.10) between metopimazine at doses of 30 mg/day or 15 mg/day and a placebo.

The second trial

▄ comparing a higher dose of metopimazine (45 mg/day) among one hundred and sixteen patients, showed a highly statistically significant therapeutic advantage over a placebo (0.001 < p < 0.01).